Seite auswählen

Focusing on its core business as part of its long-term corporate strategy Vision 2012 has brought initial success for pharmaceutical company Grünenthal.

In the first half of 2012, sales for the Grünenthal Gruppe stood at EUR 473 million (2011: EUR 483 million). Corrected by divestments, this is a 9% growth in sales compared to the same period last year.

This growth is primarily due to the continued success of the global pain products Grünenthal manufactures, especially in the strategic growth drivers in Europe Palexia (+ EUR 19 million) and Australia Versatis (+ EUR 16 million), as well as in increased royalties from Johnson & Johnson in the North American market selling the Nucynta drug under the name of tapentadol (+ EUR 10 million).

The positive developments of the business in Brazil and other Latin American countries, as well as favourable exchange rates in these Latin American countries have contributed to sales growth in the first half of 2012 (up EUR 18 million). The significant increase in operating EBITA (EUR 41 million, up 147%) is also a testament to the positive impact of the focusing strategy in fiscal 2011. 

[ilink url=“http://www.grunenthal.com/grt-web/Grunenthal_Group/Media/News/115200143.jsp?listItemID=226300120&listID=225700055&customDisplayTemplatePath=/grt-web/WEB-INF/templates/includes/presslist/press_news.jsp&activeArchive=&startIndex=1″] Link zur Quelle (Grünenthal)[/ilink]